In this important observational study from the OCEAN-Mitral Registry, Tanaka and colleagues examined a particularly difficult group of patients: individuals with advanced heart failure and secondary mitral regurgitation who underwent mitral transcatheter edge-to-edge repair, yet who also appeared theoretically suitable for durable left ventricular assist device therapy. The central clinical question was highly practical. When a patient has severe heart failure, significant functional mitral regurgitation, and advanced ventricular remodeling, is it enough to treat the valve with M-TEER, or should clinicians move earlier toward LVAD therapy instead?
The investigators used data from the Japanese multicenter OCEAN-Mitral Registry, a prospective registry involving 21 centers and patients treated between April 2018 and June 2023. From 3,764 patients who underwent M-TEER, the authors identified 129 who were considered potentially favorable LVAD candidates. These were not routine mitral regurgitation cases. They had advanced heart failure with reduced ejection fraction and secondary mitral regurgitation, often with New York Heart Association class IV symptoms, need for intravenous inotropes, or mechanical circulatory support. At the same time, patients with advanced age, severe frailty, or high HeartMate Risk Score were excluded, making this cohort a more realistic approximation of patients who could plausibly undergo durable LVAD implantation.
The baseline profile highlights how sick this population was. The mean age was 67 years, 67% were men, more than 90% had a prior heart-failure hospitalization, and more than 70% required inotropes before M-TEER. Average systolic blood pressure was only 93 mm Hg, suggesting tenuous hemodynamics. Echocardiography showed advanced cardiac remodeling and severe mitral regurgitation in many patients. In other words, these were not idealized trial patients; they represented a real-world advanced heart-failure population in whom the choice between M-TEER and LVAD can be genuinely difficult.
From a procedural standpoint, the news was encouraging. Acute procedural success exceeded 95%, and the study reports a 96% success rate overall in this subgroup. Procedure-related complications were relatively infrequent, with postoperative acute kidney injury and closure of iatrogenic atrial septal defect occurring in about 3% of cases. This supports one of the paper’s key messages: even in advanced heart-failure patients who may be LVAD candidates, M-TEER can usually be performed safely and successfully in experienced centers.
However, the long-term outcome story was more sobering. The 1-year cardiovascular death rate was 10.1%, and this rose to 38.9% by 3 years. That pattern suggests that M-TEER may offer near-term stabilization for some patients but does not fully address the underlying disease process in many of those with severe ventricular dysfunction. The paper repeatedly emphasizes that M-TEER is a focal therapy directed at the mitral valve, not a treatment for the failing left ventricle itself. In patients whose main problem is advanced ventricular remodeling rather than disproportionately severe mitral regurgitation, correcting the valve alone may not be enough.
The most important prognostic finding was the role of left ventricular size. Baseline left ventricular end-diastolic diameter was independently associated with cardiovascular death, with a hazard ratio of 1.07 per 1-mm increase. In landmark analysis, LVDd remained a significant risk factor, and the authors identified 69 mm as an important cutoff. Patients with markedly enlarged ventricles had worse survival, limited symptom improvement, and no meaningful reverse remodeling after M-TEER. Their left ventricular function also tended not to improve over time. This makes clinical sense: the more advanced the structural remodeling, the less likely a valve-focused intervention will reverse the course of end-stage heart failure.
One of the most clinically useful takeaways is that the study helps frame patient selection. The authors suggest that when LV remodeling is excessively advanced, clinicians should think carefully before choosing M-TEER over LVAD. Their interpretation aligns with the broader concept of proportionate versus disproportionate mitral regurgitation. Patients whose mitral regurgitation is severe out of proportion to ventricular size may derive more benefit from M-TEER, whereas those with massive ventricular dilation and proportionate MR may have limited long-term gain because the ventricle, not the valve, is the dominant problem.
At the same time, the paper does not argue that M-TEER should never be used in these patients. Rather, it shows that M-TEER may still be a reasonable option in selected cases, especially when LVAD implantation is less desirable because of surgical risk, device management concerns, or social limitations. But the authors are clear that these patients require very careful follow-up so clinicians do not miss the optimal timing for LVAD implantation later. That practical warning may be one of the study’s biggest contributions.
Overall, this registry study offers valuable real-world evidence. It supports procedural safety of M-TEER in a high-risk advanced heart-failure population, but it also shows that long-term efficacy is limited in those with major LV enlargement. The work does not settle the M-TEER-versus-LVAD debate, but it sharpens the decision-making framework and strongly argues for closer attention to LV size, remodeling severity, and timing of advanced heart-failure therapies.
